Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$5.61
-0.5%
$6.22
$5.41
$23.48
$485.69M0.51.20 million shs1.14 million shs
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$0.41
-1.8%
$0.45
$0.39
$2.85
$121.27M-0.251.03 million shs461,663 shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$8.82
-5.1%
$9.35
$6.42
$29.60
$468.25M1.17264,601 shs248,521 shs
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
$9.62
+5.0%
$8.08
$5.14
$29.46
$517.50MN/A329,470 shs660,442 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-0.53%-12.07%-12.75%-27.80%-73.50%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-1.79%-2.66%-8.80%-41.38%-85.18%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-5.06%-11.62%-12.15%-27.70%-49.08%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
+5.02%+5.37%+14.66%+25.59%+961,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
4.3385 of 5 stars
4.52.00.04.73.00.80.6
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
2.8461 of 5 stars
2.82.00.00.02.65.01.3
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
1.6247 of 5 stars
3.50.00.00.02.82.50.0
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
2.0929 of 5 stars
3.50.00.00.03.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.93
Moderate Buy$24.50336.72% Upside
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
1.50
Reduce$1.00143.55% Upside
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
3.00
Buy$30.83249.58% Upside
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
3.00
Buy$56.50487.32% Upside

Current Analyst Ratings Breakdown

Latest LYEL, TYRA, UPB, and KURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$33.00
5/19/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
5/2/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.00
4/29/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00 ➝ $28.00
4/28/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $40.00
4/16/2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00
4/8/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$36.00
3/31/2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/28/2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
3/13/2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00
3/6/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$27.00 ➝ $14.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$67.99M7.14N/AN/A$5.35 per share1.05
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$65K1,865.63N/AN/A$2.60 per share0.16
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/A$4.74 per shareN/A
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
$2.30M225.39N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$152.63M-$2.10N/AN/AN/AN/A-44.09%-39.57%8/14/2025 (Estimated)
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$234.63M-$1.25N/AN/AN/A-323,792.09%-34.64%-30.02%8/6/2025 (Estimated)
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$69.13M-$1.63N/AN/AN/AN/A-24.56%-23.31%8/6/2025 (Estimated)
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/AN/A0.00N/AN/AN/AN/AN/A6/11/2025 (Estimated)

Latest LYEL, TYRA, UPB, and KURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$0.19-$0.18+$0.01-$0.18N/A$0.01 million
5/8/2025Q1 2025
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.49-$0.47+$0.02-$0.47N/AN/A
5/6/2025Q1 2025
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
-$0.49-$0.51-$0.02-$0.51$0.71 million$0.57 million
5/1/2025Q1 2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million
3/27/2025Q4 2024
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.48-$0.43+$0.05-$0.43N/AN/A
3/12/2025Q4 2024
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$0.20-$0.72-$0.52-$0.72N/A$0.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/AN/AN/AN/AN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/AN/A
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
11.47
11.47
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/A
13.43
13.43
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/A
29.55
29.55
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
66.05%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
84.14%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
N/A

Insider Ownership

CompanyInsider Ownership
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6.40%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
25.10%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
15.40%
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
13.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
13086.58 million73.49 millionOptionable
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
270295.34 million218.83 millionOptionable
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2053.09 million42.81 millionOptionable
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
3853.79 millionN/AN/A

Recent News About These Companies

Upstream Bio Appoints Stacy Price As CTO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$5.61 -0.03 (-0.53%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$5.62 +0.00 (+0.09%)
As of 05/27/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Lyell Immunopharma stock logo

Lyell Immunopharma NASDAQ:LYEL

$0.41 -0.01 (-1.79%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.43 +0.02 (+4.24%)
As of 05/27/2025 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Tyra Biosciences stock logo

Tyra Biosciences NASDAQ:TYRA

$8.82 -0.47 (-5.06%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$8.82 0.00 (0.00%)
As of 05/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Upstream Bio stock logo

Upstream Bio NASDAQ:UPB

$9.62 +0.46 (+5.02%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$9.67 +0.05 (+0.56%)
As of 05/27/2025 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.